Tokyo Tape
Sign in
← M3

Quarterly report · Q3

2413.TEDINET S100SS2U
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥179.2bn2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥63.4bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥230.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥175.2bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥62.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income¥55.0bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income¥20.4bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥58.7bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥22.4bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax¥57.3bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥20.0bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥74.3bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥60.2bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥22.2bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥36.6bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥13.2bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥49.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥39.3bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥15.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥38.9bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income¥13.8bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income¥41.8bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥15.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥463.8bnat 2023-12-31Cons.Assets IFRS
Total assets¥400.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥380.7bnat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥112.7bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥91.1bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥351.1bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥309.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥297.4bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥337.1bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥302.6bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥290.7bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥143.1bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥118.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥109.8bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥35.6bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥57.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥33.4bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥26.3bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.9bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥8.6bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥13.9bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥20.7bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥53.932023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥19.452023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥72.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥57.862022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥22.422022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥53.892023-04-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.442023-10-01 → 2023-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥72.172022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥57.822022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥22.42022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio72.7%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio76.4%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 107
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31−¥2.6bn
Reconciling Itemsreconcilingrevenue2023-10-01 → 2023-12-31−¥779m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-12-31−¥2.6bn
Reconciling Itemsreconcilingrevenue intersegment2023-10-01 → 2023-12-31−¥779m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥459m
Reconciling Itemsreconcilingsegment profit2023-10-01 → 2023-12-31−¥584m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2023-04-01 → 2023-12-31¥12.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2023-10-01 → 2023-12-31¥3.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2023-04-01 → 2023-12-31¥12.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2023-10-01 → 2023-12-31¥3.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥31m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥10m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2023-04-01 → 2023-12-31¥3.9bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2023-10-01 → 2023-12-31¥549m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2023-04-01 → 2023-12-31¥20.3bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2023-10-01 → 2023-12-31¥6.5bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2023-04-01 → 2023-12-31¥20.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2023-10-01 → 2023-12-31¥6.4bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥248m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥32m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2023-04-01 → 2023-12-31¥5.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2023-10-01 → 2023-12-31¥1.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2023-04-01 → 2023-12-31¥71.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2023-10-01 → 2023-12-31¥26.0bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2023-04-01 → 2023-12-31¥69.3bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2023-10-01 → 2023-12-31¥25.3bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥2.2bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥710m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2023-04-01 → 2023-12-31¥30.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2023-10-01 → 2023-12-31¥11.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2023-04-01 → 2023-12-31¥52.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2023-10-01 → 2023-12-31¥19.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2023-04-01 → 2023-12-31¥52.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2023-10-01 → 2023-12-31¥19.5bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥15m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥4m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2023-04-01 → 2023-12-31¥12.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2023-10-01 → 2023-12-31¥5.6bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2023-04-01 → 2023-12-31¥23.4bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2023-10-01 → 2023-12-31¥8.0bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2023-04-01 → 2023-12-31¥23.4bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2023-10-01 → 2023-12-31¥8.0bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-04-01 → 2023-12-31¥10m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2023-10-01 → 2023-12-31¥3m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2023-04-01 → 2023-12-31¥2.6bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2023-10-01 → 2023-12-31¥842m
—segment totalrevenue2023-04-01 → 2023-12-31¥179.8bn
—segment totalrevenue2023-10-01 → 2023-12-31¥63.4bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥177.3bn
—segment totalrevenue external2023-10-01 → 2023-12-31¥62.7bn
—segment totalrevenue intersegment2023-04-01 → 2023-12-31¥2.5bn
—segment totalrevenue intersegment2023-10-01 → 2023-12-31¥759m
—segment totalsegment profit2023-04-01 → 2023-12-31¥54.9bn
—segment totalsegment profit2023-10-01 → 2023-12-31¥20.5bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥3.9bn
Reconciling Itemsreconcilingrevenue intersegment2022-10-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥1.1bn
Reconciling Itemsreconcilingsegment profit2022-10-01 → 2022-12-31−¥418m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥11.5bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥3.1bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥10.8bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥2.9bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥623m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥178m
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥4.2bn
jpcrp040300-q3r_E05425-000Career Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥734m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥20.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥6.6bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥20.1bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥6.4bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥521m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥174m
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.0bn
jpcrp040300-q3r_E05425-000Evidence Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥1.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-12-31¥69.8bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue2022-10-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-12-31¥67.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue external2022-10-01 → 2022-12-31¥26.5bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥2.4bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥739m
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-12-31¥32.1bn
jpcrp040300-q3r_E05425-000Medical Platformreportable segmentsegment profit2022-10-01 → 2022-12-31¥13.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-12-31¥47.3bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-12-31¥47.2bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue external2022-10-01 → 2022-12-31¥17.1bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥21m
jpcrp040300-q3r_E05425-000Overseasreportable segmentrevenue intersegment2022-10-01 → 2022-12-31¥17m
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-12-31¥13.9bn
jpcrp040300-q3r_E05425-000Overseasreportable segmentsegment profit2022-10-01 → 2022-12-31¥5.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-12-31¥27.5bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-12-31¥27.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue external2022-10-01 → 2022-12-31¥8.8bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥304m
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-12-31¥3.2bn
jpcrp040300-q3r_E05425-000Site Solutionreportable segmentsegment profit2022-10-01 → 2022-12-31¥917m
—segment totalrevenue2022-04-01 → 2022-12-31¥176.6bn
—segment totalrevenue2022-10-01 → 2022-12-31¥62.7bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥172.8bn
—segment totalrevenue external2022-10-01 → 2022-12-31¥61.6bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥3.8bn
—segment totalrevenue intersegment2022-10-01 → 2022-12-31¥1.1bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥59.5bn
—segment totalsegment profit2022-10-01 → 2022-12-31¥22.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 773
ItemContextValueUnit
Intersegment revenue IFRSPrior1QuarterDuration_ReportableSegmentsMember1108000000JPY
Intersegment revenue IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember24000000JPY
Intersegment revenue IFRSPrior1QuarterDuration_ReconcilingItemsMember-1132000000JPY
Intersegment revenue IFRSPrior1QuarterDuration－JPY
Revenue IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000MedicalPlatformReportableSegmentMember27226000000JPY
Revenue IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000EvidenceSolutionReportableSegmentMember6598000000JPY
Revenue IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember3093000000JPY
Revenue IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember8751000000JPY
Revenue IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember17073000000JPY
Revenue IFRSPrior1QuarterDuration_ReportableSegmentsMember62741000000JPY
Revenue IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember929000000JPY
Revenue IFRSPrior1QuarterDuration_ReconcilingItemsMember-1132000000JPY
Revenue IFRSPrior1QuarterDuration62538000000JPY
Operating profit loss IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000MedicalPlatformReportableSegmentMember13326000000JPY
Operating profit loss IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000EvidenceSolutionReportableSegmentMember1799000000JPY
Operating profit loss IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember734000000JPY
Operating profit loss IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember917000000JPY
Operating profit loss IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember5806000000JPY
Operating profit loss IFRSPrior1QuarterDuration_ReportableSegmentsMember22582000000JPY
Operating profit loss IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember277000000JPY
Operating profit loss IFRSPrior1QuarterDuration_ReconcilingItemsMember-418000000JPY
Operating profit loss IFRSPrior1QuarterDuration22441000000JPY
Finance income and expenses net IFRSPrior1QuarterDuration-258000000JPY
Profit loss before tax IFRSPrior1QuarterDuration22183000000JPY
Depreciation and amortization operating expenses IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000MedicalPlatformReportableSegmentMember703000000JPY
Depreciation and amortization operating expenses IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000EvidenceSolutionReportableSegmentMember139000000JPY
Depreciation and amortization operating expenses IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember25000000JPY
Depreciation and amortization operating expenses IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember248000000JPY
Depreciation and amortization operating expenses IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember668000000JPY
Depreciation and amortization operating expenses IFRSPrior1QuarterDuration_ReportableSegmentsMember1782000000JPY
Depreciation and amortization operating expenses IFRSPrior1QuarterDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember67000000JPY
Depreciation and amortization operating expenses IFRSPrior1QuarterDuration_ReconcilingItemsMember－JPY
Depreciation and amortization operating expenses IFRSPrior1QuarterDuration1849000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000MedicalPlatformReportableSegmentMember25267000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000EvidenceSolutionReportableSegmentMember6445000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember3486000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember8018000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember19464000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_ReportableSegmentsMember62681000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember713000000JPY
Revenue from external customers IFRSCurrentQuarterDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentQuarterDuration63394000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000MedicalPlatformReportableSegmentMember710000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000EvidenceSolutionReportableSegmentMember32000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000CareerSolutionReportableSegmentMember10000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000SiteSolutionReportableSegmentMember3000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OverseasReportableSegmentMember4000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_ReportableSegmentsMember759000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_jpcrp040300-q3r_E05425-000OtherEmergingBusinessMember20000000JPY
Intersegment revenue IFRSCurrentQuarterDuration_ReconcilingItemsMember-779000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass